Education
About Us
Working with TipRanks
Follow Us
Medpace Holdings (MEDP)
NASDAQ:MEDP
MEDP Stock Chart & Stats
$423.93
$7.21(2.08%)
At close: 4:00 PM EST
$423.93
$7.21(2.08%)
Day’s Range― - ―
52-Week Range$250.05 - $628.92
Previous CloseN/A
Volume64.09K
Average Volume (3M)251.43K
Market Cap
$12.03B
Enterprise Value$11.81B
Total Cash (Recent Filing)$497.05M
Total Debt (Recent Filing)$113.64M
Price to Earnings (P/E)27.7
Beta1.13
Next Earnings
Apr 27, 2026EPS Estimate
3.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.67
Shares Outstanding28,381,283
10 Day Avg. Volume361,147
30 Day Avg. Volume251,428
Financial Highlights & Ratios
PEG Ratio1.82
Price to Book (P/B)35.29
Price to Sales (P/S)6.40
P/FCF Ratio23.76
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue4.67
Enterprise Value/Gross Profit15.53
Enterprise Value/Ebitda21.40
Forecast
1Y Price Target
$538.33Price Target Upside26.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biotech Funding ReboundRebound in biotech funding is expected to translate into higher bookings for the company after a customary lag, supporting future revenue growth.
Conservative Balance SheetA conservative balance sheet and cautious accounting approach reduce financial and execution risk, improving resilience during sector volatility.
Faster Backlog ConversionHigher backlog conversion driven by an increase in faster-moving metabolic trials supports quicker revenue realization and strengthens revenue visibility.
Bears Say
Bookings And Order IntakeA significant bookings shortfall indicates new business awards are not keeping pace with billed revenue, reducing revenue visibility and growth confidence.
Elevated CancellationsElevated cancellation rates in the backlog eliminate expected future revenue and create a meaningful headwind to growth and earnings.
Revenue Quality ConcernsRevenue beats driven mainly by large pass-through items rather than core service fees suggest lower quality of revenue and raise questions about sustainable profitability.
Medpace Holdings News
MEDP FAQ
What was Medpace Holdings’s price range in the past 12 months?
Medpace Holdings lowest stock price was $250.05 and its highest was $628.91 in the past 12 months.
What is Medpace Holdings’s market cap?
Medpace Holdings’s market cap is $12.03B.
When is Medpace Holdings’s upcoming earnings report date?
Medpace Holdings’s upcoming earnings report date is Apr 27, 2026 which is in 71 days.
How were Medpace Holdings’s earnings last quarter?
Medpace Holdings released its earnings results on Feb 09, 2026. The company reported $4.67 earnings per share for the quarter, beating the consensus estimate of $4.185 by $0.485.
Is Medpace Holdings overvalued?
According to Wall Street analysts Medpace Holdings’s price is currently Undervalued.
Does Medpace Holdings pay dividends?
Medpace Holdings does not currently pay dividends.
What is Medpace Holdings’s EPS estimate?
Medpace Holdings’s EPS estimate is 3.94.
How many shares outstanding does Medpace Holdings have?
Medpace Holdings has 28,381,283 shares outstanding.
What happened to Medpace Holdings’s price movement after its last earnings report?
Medpace Holdings reported an EPS of $4.67 in its last earnings report, beating expectations of $4.185. Following the earnings report the stock price went down -15.895%.
Which hedge fund is a major shareholder of Medpace Holdings?
Currently, no hedge funds are holding shares in MEDP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medpace Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$538.33 (26.99% Upside)
$538.33 (26.99% Upside)
Blogger Sentiment
Bullish
MEDP Sentiment 83%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 51.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $185.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 11.1%
Last 30 Days ▼ 11.1%
News Sentiment
Neutral
Bullish news 52%
Bearish news 48%
Bearish news 48%
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.30%
12-Months-Change
Fundamentals
Return on Equity
70.23%
Trailing 12-Months
Asset Growth
-5.97%
Trailing 12-Months
Company Description
Medpace Holdings
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
MEDP Company Deck
MEDP Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple clear strengths: robust revenue and EBITDA growth in Q4 and full year 2025, strong cash generation, aggressive share repurchases, a healthy backlog, and positive 2026 guidance. Key near-term challenges include a spike in cancellations (notably in metabolic programs), modest margin compression due to higher reimbursable costs, and elevated pass-through exposure that may moderate reported top-line cadence early in 2026. Management expects hiring above 2025 levels but plans to rely on improved retention and productivity to support margins, and guidance assumes normalized cancellation rates. On balance, the company's fundamental growth, cash flow, and shareholder return actions outweigh the transient operational headwinds discussed on the call.View all MEDP earnings summariesMEDP Revenue Breakdown
98.00% U.S.
2.00% Other
MEDP Stock 12 Month Forecast
Average Price Target
$538.33
▲(26.99% Upside)
Technical Analysis
Ownership Overview
19.39% Insiders
20.64% Mutual Funds
18.48% Other Institutional Investors
19.47% Public Companies and
Individual Investors